Abstract: It relates to the combination of PIM kinase inhibitor and a KRAS inhibitor for use in treating cancer, in a subject in need thereof. Also provided are compositions or kits comprising same. Furthermore, it also relates to a PIM kinase inhibitor for use in treating cancer with KRAS mutation in a human subject in need thereof.

Abstract: The present application belongs to the technical field of batteries, and provides a battery cell, a battery, and an electric device. The battery cell includes an electrode body, tabs, and connectors. The tab has a first side edge and a second side edge opposite to each other, the first side edge of the tab is connected to the electrode body, and the connector is connected to the second side edge of the tab. A bending portion is provided between the first side edge and the second side edge of the tab. According to the battery cell provided in the present application, the possibility that the tab is pulled and broken when the battery cell expands can be reduced, thereby improving the reliability of the battery cell.

Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments, wherein the presence of a mutation to AKT correlates with sensitivity of the cancer to AKT inhibitors, such as (S)-2-(4-chlorophenyl)-1-(4-((5R,7R)-7-hydroxy-5-methyl-6,7-dihydro-5H-cyclopenta[d]pyrimidin-4-yl)piperazin-1-yl)-3-(isopropylamino)propan-1-one.

Abstract: A positive electrode plate includes a positive active material layer. The positive active material layer includes a first positive active material and a second positive active material. The first positive active material and the second positive active material each independently include a lithium-containing transition metal oxide. An outer surface of the second positive active material includes a passivation layer; and/or an average particle diameter Dv50 of the second positive active material is greater than an average particle diameter Dv50 of the first positive active material.

Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

Abstract: Provided herein are combination therapies comprising GDC-9545 and ipatasertib for treating locally advanced breast cancer or metastatic breast cancer.

Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

Abstract: A media management system including an application layer, a system layer, and a solid state drive (SSD) storage layer. The application layer includes a media data analytics application configured to assign a classification code to a data file. The system layer is in communication with the application layer. The system layer includes a file system configured to issue a write command to a SSD controller. The write command includes the classification code of the data file. The SSD storage layer includes the SSD controller and erasable blocks. The SSD controller is configured to write the data file to one of the erasable blocks based on the classification code of the data file in the write command. In an embodiment, the SSD controller is configured to write the data file to one of the erasable blocks storing other data files also having the classification code.

Abstract: Provided herein are combination therapies comprising an ATP competitive AKT inhibitor, fulvestrant, and CDK4/6 inhibitor for use in treating hormone receptor positive and HER2 negative locally advanced unresectable or metastatic breast cancer.

Abstract: Methods for identifying or diagnosing AKT inhibitor resistant cancers and methods an compositions for treating.

Abstract: A media management system including an application layer, a system layer, and a solid state drive (SSD) storage layer. The application layer includes a media data analytics application configured to assign a classification code to a data file. The system layer is in communication with the application layer. The system layer includes a file system configured to issue a write command to a SSD controller. The write command includes the classification code of the data file. The SSD storage layer includes the SSD controller and erasable blocks. The SSD controller is configured to write the data file to one of the erasable blocks based on the classification code of the data file in the write command. In an embodiment, the SSD controller is configured to write the data file to one of the erasable blocks storing other data files also having the classification code.

Abstract: The present invention relates to a method and system for quantitative defacing of a QR Code. Defacing of the method includes data and error correction code word defacing, boundary defacing, position detection pattern defacing, correction pattern defacing, positioning pattern defacing, version information defacing, and format information defacing. Quantitative defacing varies with the defacing patterns and positions of a barcode. The defacing degree of the QR Code is not greater than the capability of the barcode for correcting error codes. The number of coding characters of the QR Code is required to be equal to the character number of a data code word which is specified by a current barcode version and correction grade, and the situation of adding filling characters does not exist. Defacing of the data and error correction code words does not include defacing of remaining bits. Defacing patterns include pre-stage printing defacing and rear-stage actual defacing.

Abstract: Provided herein are biomarkers, and combinations of biomarkers, for predicting sensitivity to cancer treatments.

Abstract: Methods for identifying or diagnosing AKT inhibitor resistant cancers and methods an compositions for treating.

Abstract: In one embodiment, a method of serving media includes receiving a request to serve a cacheable media content to a user equipment at a second media server deployed in a second layer2 access network. The request is received around when the user equipment is handed-off from a first layer2 node in a first layer2 access network to a second layer2 node in the second layer2 access network and when a streaming session of the cacheable media content to the user equipment from a first media server is terminated. The method further includes determining if the cacheable media content is stored in a cache of the second media server, and serving the cacheable media content from the cache of the second media server to the user equipment if the media content is stored in the cache of the second media server.

Abstract: The invention provides combinations comprising a) compound of formula I: or a pharmaceutically acceptable salt thereof wherein R1, R2, R5, R10, and A have any of the values defined in the specification; and b) one or more agents selected from 5-FU, a platinum agent, leucovorin, irinotecan, docetaxel, doxorubicin, gemcitabine, SN-38, capecitabine, temozolomide, paclitaxel, bevacizumab, pertuzumab, tamoxifen, rapamycin and lapatinib. The combinations are particularly useful for treating hyperproliferative disorders, such as cancer.

Abstract: A media management system including an application layer, a system layer, and a solid state drive (SSD) storage layer. The application layer includes a media data analytics application configured to assign a classification code to a data file. The system layer is in communication with the application layer. The system layer includes a file system configured to issue a write command to a SSD controller. The write command includes the classification code of the data file. The SSD storage layer includes the SSD controller and erasable blocks. The SSD controller is configured to write the data file to one of the erasable blocks based on the classification code of the data file in the write command. In an embodiment, the SSD controller is configured to write the data file to one of the erasable blocks storing other data files also having the classification code.

Abstract: Methods for identifying or diagnosing AKT inhibitor resistant cancers and methods an compositions for treating.